Roche has gained conditional marketing authorisation for Lunsumio (mosunetuzumab) in the European Union, marking the first approval of a CD20xCD3 T-cell engaging bispecific antibody anywhere in the world.
The approval helps keep the company ahead of its rivals in the same class, most notably Genmab/AbbVie’s epcoritamab,...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
